Skip to content

A Comparative Clinical Study of Sarpagandha Tablets and Bloodletting Therapy in the Management of Primary High Blood Pressure.

A Randomised Comparative Clinical Study On Effect Of Sarpagandha Ghana Vati And Siravedha in Vyanabala Vaishamya With Special Reference To Primary Hypertension. - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/01/102345
Enrollment
60
Registered
2026-01-28
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

None listed

Sponsors

National Institute of Ayurved
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients between the age group of 18 to 60 years, irrespective of their gender and socio-economic status. 2.Patients who are willing to sign consent form for the clinical trial. 3.Patients having no known complications of disease. 4.Normal BT and CT values. 5.Pre diagnosed patients taking conventional drugs at least 3 mounths and still having hypertension in above criteria will also be included and their countinuing treatment will also be continuted along with trial medicine/procedure.

Exclusion criteria

Exclusion criteria: 1.Patients below age of 18 years and above 60 years. 2.Patients having secondary hypertension caused by kidney disease, adrenal disease, thyroid disorder etc. 3.Patients with anemia and bleeding disorders. 4.Pregnant women and lactating mothers. 5.Patients with history of serious liver diseases, Hypertensive retinopathy.

Design outcomes

Primary

MeasureTime frame
Changes in Blood Pressure (systolic & diastolic).Timepoint: Baseline 1th day.

Secondary

MeasureTime frame
Changes in subjective criteria Shirashool(headache),Klama(fatigue),Hritspandan(palpitation),Bhrama(giddiness),Anidra(insomnia), Krodha (excessive anger). Timepoint: Baseline 30th day, end of treatment period.

Countries

India

Contacts

Public ContactDr Udai Raj Saroj Sir

National Institute Of Ayurveda, Jaipur

ursarojayu@gmail.com9413063803

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026